2026
PCK – Notification regarding unquoted securities – 28 May 2026
PCK – Initial Director’s Interest Notice – 26 May 2026
PCK – Lil Bianchi appointed Non-Executive Chair of PainChek – 25 May 2026
PCK – Proposed issue of securities – 22 May 2026
PCK – PainChek secures A$5.5m note to fund US expansion – 22 May 2026
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 30 April 2026
PCK – Notification of cessation of securities – 14 April 2026
PCK – Landmark Sabra North America deployment targeting 20k beds – 14 April 2026
PCK – Notification of cessation of securities – 27 March 2026
PCK – PainChek reports material sales momentum in UK – 26 March 2026
PCK – PainChek to present at NWR Virtual Healthcare Conference – 24 March 2026
PCK – Notification of cessation of securities – 4 March 2026
PCK – Half Yearly Report and Accounts – 27 February 2026
PCK – Update – Notification regarding unquoted securities – 12 February 2026
PCK – Notification regarding unquoted securities – 11 February 2026
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 30 January 2026
PCK – PainChek Business Update – 30 January 2026
PCK – Quarterly update & Appendix 4C webinar 10:30am AEDT Friday 30 January 2026
2025
PCK – Change of Director’s Interest Notice x 5 – 30 December 2025
PCK – Notification of cessation of securities – 30 December 2025
PCK – Application for quotation of securities – 24 December 2025
PCK – Notice under s708A(5)(e) of the Corporations Act 2001 (Cth) – 23 December 2025
PCK – Change of Director’s Interest Notice x2 – 23 December 2025
PCK – Application for quotation of securities – 23 December 2025
PCK – Application for quotation of securities – 12 December 2025
PCK – Results of Meeting – 26 November 2025
PCK – AGM Presentation – 26 November 2025
PCK – Application for quotation of securities – 25 November 2025
PCK AGM watching the live feed – 24 November 2025
PCK – Application for quotation of securities – 7 November 2025
PCK – Investor Presentation – 31 October 2025
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 31 October 2025
PCK – Notification of cessation of securities – 30 October 2025
PCK – Quarterly update & Appendix 4C webinar – 29 October 2025
PCK – Change of Director’s Interest Notice – 27 October 2025
PCK – Consolidation/Split – 24 October 2025
Confirmation of Release – PCK – Application for quotation of securities – 24 October 2025
PCK – Notice of Annual General Meeting/Proxy Form – 24 October 2025
PCK – Application for quotation of securities – 17 October 2025
PCK – Key hire to drive Infant App in $15Bn addressable market – 17 October 2025
PCK – Response to ASX Aware Letter – 16 October 2025
PCK – Application for quotation of securities – 14 October 2025
PCK – PainChek Secures First US Customer Following FDA Clearance – 13 October 2025
PCK – Application for quotation of securities – 10 October 2025
PCK – Application for quotation of securities – 8 October 2025
PCK – PainChek FDA Cleared to Commence Sales in US$100M US Market – 8 October 2025
PCK – Trading Halt – 7 October 2025
PCK – Notification of cessation of securities – 2 October 2025
PCK – Change of Director’s Interest Notice – 1 October 2025
PCK – Corporate Governance Statement and Appendix 4G 2025 – 30 September 2025
PCK – Annual Report to shareholders – 30 September 2025
PCK – Application for quotation of securities – 29 September 2025
PCK – Change of Director’s Interest Notice x3 – 19 September 2025
PCK – Compelling Clinical and Economic Results in Scottish Pilot – 17 September 2025
PCK – Application for quotation of securities – 15 September 2025
PCK – Preliminary Final Report – 29 August 2025
PCK – Notice under Section 708A(5)(e) of the Corporations Act 2001 – 5 August 2025
PCK – Application for quotation of securities – 5 August 2025
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 31 July 2025
PCK – Quarterly update & Appendix 4C webinar – 29 July 2025
PCK – Investor Presentation – 28 July 2025
PCK – Proposed issue of securities – 28 July 2025
PCK – Strongly Supported A$7.5m Placement to Drive Int. Growth – 28 July 2025
PCK – Trading Halt – 24 July 2025
PCK – Final US FDA De Novo Clearance Submission Completed – 21 July 2025
PCK – Notification of cessation of securities – 11 July 2025
PCK – Change in Directors’ Interest Notice x 5 – 7 July 2025
PCK – Notification regarding unquoted securities – 7 July 2025
PainChek Reports Strong Quarterly Sales Growth – 3 July 2025
PCK – Application for quotation of securities – 6 June 2025
PCK – PainChek has productive final FDA De Novo clearance meeting – 5 June 2025
PCK – PainChek partners with Eldermark to expand US market reach – 27 May 2025
PCK – PainChek appoints head of Business Development for US market – 20 May 2025
PCK – Notification regarding unquoted securities – 19 May 2025
PCK – Notification of cessation of securities – 19 May 2025
PCK – Quarterly Investor Presentation April 2025
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 30 April 2025
PCK – Quarterly update and Appendix 4C webinar – 29 April 2025
PCK – R&D Tax Refund, FDA Review of Adult App & Infant App Launch – 16 April 2025
PCK – Appendix 2A – Application for quotation of securities – 27 March 2025
PCK – Update to previous announcement – 17 March 2025
PCK – PainChek NWR Investor Presentation Video – 17 March 2025
PCK – PainChek to present at NWR Virtual Healthcare – 17 March 2025
PCK – Notification regarding unquoted securities – 6 March 2025
PCK – Application for quotation of securities – 6 March 2025
PCK – Notification regarding unquoted securities – 5 March 2025
PCK – Half Yearly Report and Accounts – 28 February 2025
PCK – Results of Meeting – 26 February 2025
PCK – Quarterly Update and Appendix 4C – 31 January 2025
PCK – Quarterly update and Appendix 4C webinar – 30 January 2025
PCK – Notice of General Meeting/Proxy Form – 24 January 2025
